Prot #16-214-02: A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignan

Project: Research project

Project Details

StatusActive
Effective start/end date3/20/193/20/22

Funding

  • Covance Inc. (Prot #16-214-02)
  • Nektar Therapeutics (Prot #16-214-02)